Table 3.
Outcomes measures of the open label phase.
| Outcomes | FR (n = 27) | CW (n = 27) | p-value |
|---|---|---|---|
| ANNUAL RELAPSE RATE | |||
| Mean ± SD | 0.20 ± 0.21 | 0.40 ± 0.73 | 0.276a |
| Median (IQR) | 0.14 (0–0.37) | 0.25 (0–0.50) | |
| Range | 0–0.7 | 0–3.5 | |
| EDSS SCORE | |||
| Mean ± SD | 2.42 ± 2.14 | 2.40 ± 2.29 | 0.691a |
| Median (IQR) | 1.5 (1–3.5) | 1.5 (1–3.5) | |
| Range | 0–7 | 0–7 | |
| SHIFTING TO A PROGRESSIVE DISEASE | |||
| N (%) | 4 (0.14) | 5 (0.18) | 0.715b |
a
Non-parametric Wilcoxon rank-sum test (for variables with non-normal distribution).
b
Chi-square test for categorical variables.